Pharmaceuticals News and Research

RSS

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases today launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study, which will be conducted in Liberia and the United States, is a randomized controlled trial enrolling adults and children with known Ebola virus infection.

27 Feb 2015

ERT signs definitive agreement to acquire PHT

ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, and PHT Corporation, the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research, announced today that they have signed a definitive agreement under which ERT will acquire PHT.

27 Feb 2015

Single-step fermentative method may facilitate industrial-scale statin drug production

University of Manchester researchers, together with industrial partner DSM, have developed a single-step fermentative method for the production of leading cholesterol-lowering drug, pravastatin, which will facilitate industrial-scale statin drug production.

27 Feb 2015

Researchers show how human antibodies can neutralize Marburg virus

Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola.

27 Feb 2015

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO).

26 Feb 2015

Lyric announces initial closing of $20.4 million Series A financing round

Lyric Pharmaceuticals Inc. today announced the initial closing of a Series A financing round totaling $20.4 million. The financing, co-led by RiverVest Venture Partners, Sante Ventures and Third Point Ventures, includes participation by Aperture Venture Partners.

26 Feb 2015

Cipher acquires worldwide rights to three products from Astion

Cipher Pharmaceuticals Inc. today announced it has strengthened its product pipeline by acquiring the worldwide rights to three products from Astion Pharma, a Denmark-based specialty pharmaceutical company.

26 Feb 2015

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital.

26 Feb 2015

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the European Medicines Agency has granted orphan drug designation for alvocidib for the treatment of patients with acute myeloid leukemia (AML).

26 Feb 2015

New study identifies genetic link to peanut allergy

Researchers have pinpointed a region in the human genome associated with peanut allergy in U.S. children, offering strong evidence that genes can play a role in the development of food allergies.

25 Feb 2015

Gates Foundation awards $2.5 million to support development of vaccine-filled microneedles

The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio.

25 Feb 2015

Indiana University study reveals connection between mussels and muscles

An Indiana University study has revealed that there may be a greater connection between mussels and muscles than previously thought.

25 Feb 2015

Two Glenmark manufacturing facilities in India win Greentech Environment Gold Award - 2015

Two manufacturing facilities of Glenmark located in Goa and Nashik bagged the prestigious 'Greentech Environment Gold Award - 2015' for Excellence in Environment Management at a ceremony in Kolkata recently. Greentech Environment Awards are presented ever year to companies/units in India demonstrating the highest level of commitment to Environmental Management across different sectors.

25 Feb 2015

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg.

25 Feb 2015

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures.

24 Feb 2015

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).

24 Feb 2015

N30 Pharmaceuticals becomes Nivalis Therapeutics

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the development of product candidates for cystic fibrosis (CF), announced today that the Company has changed its name to Nivalis Therapeutics, Inc. The Company's lead product candidate, N91115, is a novel inhibitor of S-nitrosoglutathione reductase (GSNOR).

24 Feb 2015

Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Medicago, a leading company in the development and production of plant-based vaccines and therapeutics, announced today that it has received a task order from the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp, from Mapp Biopharmaceutical.

24 Feb 2015

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2014.

24 Feb 2015

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.

24 Feb 2015

Pharmaceuticals News and Research

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

ERT signs definitive agreement to acquire PHT

Single-step fermentative method may facilitate industrial-scale statin drug production

Researchers show how human antibodies can neutralize Marburg virus

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Lyric announces initial closing of $20.4 million Series A financing round

Cipher acquires worldwide rights to three products from Astion

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

New study identifies genetic link to peanut allergy

Gates Foundation awards $2.5 million to support development of vaccine-filled microneedles

Indiana University study reveals connection between mussels and muscles

Two Glenmark manufacturing facilities in India win Greentech Environment Gold Award - 2015

Actavis files ANDA to market Budesonide Extended-release Tablets

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

N30 Pharmaceuticals becomes Nivalis Therapeutics

Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

NeoGenomics' revenue increases 36% to $25.0 million in fourth quarter 2014

Shire announces acquisition of Meritage Pharma

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring